H.C. Wainwright cuts BioMarin stock price target after trial miss By Investing.com

H.C. Wainwright cut BioMarin's price target to $50 from $55 and kept a Neutral rating after the company's Phase 3 ENERGY 3 study for BMN 401 failed to show clinical benefit despite meeting one biochemical endpoint. The trial missed its key radiographic endpoint and showed no positive trends on secondary measures, prompting the firm to remove BMN 401 from its model. BioMarin also recently reported Q1 2026 EPS of $0.76 versus $0.74 expected and revenue of $766 million versus $755.94 million, but the article's focus is the setback for BMN 401 and the resulting cautious analyst stance.

Analysis

The market is treating this as a validation event for BioMarin’s growth model, but the bigger signal is that the company’s pipeline is becoming increasingly dependent on one commercial asset and one hard-to-replicate orphan franchise. When a high-margin pipeline program fails to move from biomarker to outcome in pediatrics, investors usually compress the value of the entire adjacent rare-disease platform, not just the failed asset, because future probability-weighted returns on follow-on indications get marked down.

Near term, the setup is more about multiple compression than earnings risk. A stock already pinned near the low end of its range can still fall another 10-15% if generalist holders de-risk and sell into any sign that the growth algorithm has become less durable; that tends to happen over days to weeks, before fundamentals fully reset. The offset is that the core franchise can remain resilient enough to prevent a deeper drawdown, which makes this a better short-vol or pair-trade situation than a naked short.

The second-order winner is not a direct competitor so much as any company with a cleaner rare-disease readthrough story: investors tend to rotate capital from “science-risk” names into names with clearer commercial execution. For Goldman’s read-through, the more important implication is that competitive pressure on the existing franchise is now being evaluated with a higher discount rate; if management cannot show durable patient growth or new label expansion, the market will likely pay less for each incremental patient added over the next 6-12 months.

The contrarian angle is that the miss may already be sufficiently embedded in expectations that the stock reacts more to what management says about capital allocation than to the failed endpoint itself. If they credibly pivot away from chasing low-probability extensions and toward protecting the core asset, the downside could stabilize quickly. But if guidance implies another costly development reset, the name likely stays range-bound to lower for multiple quarters.

Key Decisions for Investors

• Short BMRN on any post-news bounce back toward the prior support-turned-resistance zone; target 8-12% downside over 2-6 weeks, with a tight stop if management reiterates strong 2026-2027 franchise growth.
• Pair trade: long a cleaner rare-disease peer with visible launch/multi-year growth and short BMRN for 1-3 months; the trade should capture multiple compression from pipeline disappointment while reducing market beta.
• Sell BMRN downside puts or structure a put spread 1-3 months out if implied volatility spikes; the stock’s near-term risk is real, but the failure may be partially priced, making defined-risk premium selling attractive.
• Avoid buying the dip until management provides a clear post-failure capital allocation roadmap; if the company signals an expensive rework of the program, re-enter only after guidance resets the base case.
• If holding long-term BMRN, hedge with a 3-6 month collar: finance downside protection by selling out-of-the-money calls, because the stock may remain range-bound even if the core franchise is intact.